SCHEMBL691666

SCHEMBL691666

CC(C)(C)OC(=O)n1ccc2ccccc21

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.51
TSHR P16473 1/20 0.51
RAB9A P51151 1/20 0.51
HTR3E A5X5Y0 1/20 0.47
HTR3B O95264 1/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNA7 P36544 1/20 0.47
CHRNA4 P43681 1/20 0.47
HTR3A P46098 1/20 0.47
HTR3D Q70Z44 1/20 0.47
HTR3C Q8WXA8 1/20 0.47
BCHE P06276 1/20 0.46
NR1H2 P55055 6/20 0.44
BUB1 O43683 1/20 0.43
ACLY P53396 1/20 0.42
PIK3CD O00329 1/20 0.42
ABL1 P00519 1/20 0.42
EGFR P00533 1/20 0.42
HCK P08631 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29701136 1.00 NOTUM (0.59) NOTUML3MBTL1TSHRRAB9AHTR3E
SCHEMBL28085950 0.98 NOTUM (0.57) NOTUML3MBTL1TSHRRAB9AHTR3E
SCHEMBL2458509 0.81 ACLY (0.52) NR1H2ACLYPIK3CDABL1EGFR
SCHEMBL30711215 0.81 NOTUM (0.65) NOTUML3MBTL1TSHRRAB9AHTR3E
SCHEMBL1173678 0.81 NOTUM (0.65) NOTUML3MBTL1TSHRRAB9AHTR3E
SCHEMBL25010272 0.80 NR1H2 (0.48) NR1H2NR1H3
SCHEMBL26698290 0.80 NOTUM (0.42) NOTUML3MBTL1TSHRRAB9AHTR3E
SCHEMBL4930238 0.80 KDM4E (0.44) NOTUML3MBTL1BCHEBUB1ACLY
SCHEMBL24476978 0.80 L3MBTL1 (0.51) NOTUML3MBTL1BCHEBUB1HSP90AA1
SCHEMBL1273077 0.80 HTR6 (0.49) NOTUML3MBTL1BCHENR1H2BUB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118598851-A 5-Aminoindole chalcone compound and preparation method and application thereof 平顶山学院 2024-09-06 CN claimed
CN-103570688-B 2,5-diaminomethyl pyrazine compounds, its pharmaceutical composition, preparation method and purposes 中国科学院上海药物研究所 2016-06-08 CN claimed
CN-101535299-A 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS INC (US) 2009-09-16 CN claimed
US-12559455-B2 Compound as a UBR box domain ligand AUTOTAC INC. (KR) 2026-02-24 US disclosed
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME MONTE ROSA THERAPEUTICS AG (CH) 2025-05-29 US disclosed
WO-2025087365-A1 METTL3 INHIBITOR 杭州邦顺制药有限公司 2025-05-01 WO disclosed
CN-119899188-A METTL3 inhibitors 杭州邦顺制药有限公司 2025-04-29 CN disclosed
CN-119816491-A New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2025-04-11 CN disclosed
CN-119798277-A Novel isoxazolo pyrimidine derivative with anti-novel coronavirus activity and preparation method and application thereof 吉林大学 2025-04-11 CN disclosed
WO-2025067477-A1 CYCLOPEPTIDE OF ACINETOBACTER BAUMANNII AND USE THEREOF 武汉人福创新药物研发中心有限公司 2025-04-03 WO disclosed
CN-119708122-A Cyclic peptide for resisting Acinetobacter baumannii and application thereof 武汉人福创新药物研发中心有限公司 2025-03-28 CN disclosed
WO-2001044235-A2 AGENTS AND METHODS FOR THE TREATMENT OF PROLIFERATIVE DISEASES ELI LILLY AND COMPANY (US) 2001-06-21 WO disclosed
CN-1291892-A Substituted oxoazaheterocyclyl factor Xa inhibitors AWENTIS PHARMACEUTICAL INC (US) 2001-04-18 CN disclosed
CN-1222911-A Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation PHARMACIA & UPJOHN SPA (IT) 1999-07-14 CN disclosed
EP-0909271-A1 INDOLYL-PYRROLYDENEMETHYLPYRROLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION PHARMACIA & UPJOHN S.p.A. (IT) 1999-04-21 EP disclosed
US-5859007-A TREATMENT OF DIABETES, OBESITY GLAXO WELLCOME INC. (US) 1999-01-12 US disclosed
WO-1998040380-A1 INDOLYL-PYRROLYDENEMETHYLPYRROLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION PHARMACIA & UPJOHN S.P.A. (IT) 1998-09-17 WO disclosed
EP-0411150-B1 INDOLE DERIVATIVES, PREPARATION THEREOF, AND DRUG FOR PREVENTING AND TREATING NEPHRITIS CONTAINING SAME OTSUKA PHARMA CO LTD (JP) 1996-11-27 EP disclosed
EP-0284174-B1 THERAPEUTIC PREPARATIONS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-07-29 EP disclosed
EP-0284174-A1 Therapeutic preparations IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1988-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559455-B2 Compound as a UBR box domain ligand UBR4, UBTF, UBQLN1 NOTUM 4607/4885L3MBTL1 1436/4885TSHR 1240/4885
US-20250171420-A1 MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME PSMA1, CSNK1G1, CSNK1A1 NOTUM 2701/4885L3MBTL1 1228/4885TSHR 4501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.